The chairman of the Dutch research-based drug industry associationNefarma, Mr G Worm, has said that health care insurers should in future offer a basic basket of drugs. While in principle all drugs should be available to the insured, extra quality should be available if patients pay extra or insure themselves further against such costs, he said.
Government measures prevent the introduction of new drugs into the insurers' basket, he said. Other disincentives are the price law and the need for the company to prove that new drugs have an economic advantage over existing products.
Meantime the D66 government party says that sick funds should be accessible only to people whose income is too small for them to afford private insurers. Total taxable income would be taken into account, not just wages and salaries, meaning that independent workers such as small shopkeepers would have access to the funds while families with several incomes would have to rely on private insurers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze